SEC Form 4 · accession 0001209191-17-022346
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Mar 20, 2017 | M | 5,933 | $9.05 | A | 21,403 | D | |
| Common stock | Mar 20, 2017 | S | 5,933 | $55.00 | D | 15,470 | D | |
| Common stock | Mar 20, 2017 | M | 505 | $0.4675 | A | 15,975 | D | |
| Common stock | Mar 20, 2017 | S | 505 | $55.00 | D | 15,470 | D | |
| Common stockF3 | holding | — | — | — | 31,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common stock (right to buy)F4 | $0.4675 | Mar 20, 2017 | M | 505 | D | — | Dec 6, 2020 | Common stock | 505 | 4,969 | D |
| Common stock (right to buy)F5 | $9.05 | Mar 20, 2017 | M | 5,933 | D | — | Apr 29, 2023 | Common stock | 5,933 | 48,157 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee.
- F4This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.
- F5This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.